Literature DB >> 6887757

Antimicrobial prophylaxis in acute leukaemia: prospective randomized study comparing two methods of selective decontamination.

E Kurrle, S Bhaduri, D Krieger, H Pflieger, H Heimpel.   

Abstract

In a prospective study the efficacy of two regimens for selective decontamination of the digestive tract was studied in patients with acute leukaemia during remission induction therapy. Seventy-eight patients were randomized to receive either a combination of cotrimoxazole, polymyxin B and nystatin (group A) or a combination of nalidixic acid, polymyxin B, neomycin and nystatin. With both regimens the gastrointestinal tract could be decontaminated equally effectively from potential pathogens. In the oropharyngeal region the decontamination from Enterobacteriaceae was significantly better in group A (P less than 0.01). In both groups less than 10% of the acquired infections were caused by gram-negative bacilli and no gram-negative septicaemia occurred in either group. The median time interval until the first acquired infection was 17 days in group A and 36 days in group B, respectively (P less than 0.05). It is concluded that regimen A might be more effective than regimen B though both regimens prevent reliably severe gram-negative infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6887757     DOI: 10.1007/bf01487614

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  26 in total

1.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results.

Authors:  M Dietrich; W Gaus; J Vossen; D van der Waaij; F Wendt
Journal:  Infection       Date:  1977       Impact factor: 3.553

2.  Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains.

Authors:  J Klastersky; L Debusscher; D Weerts; D Daneau
Journal:  Pathol Biol (Paris)       Date:  1974-01

3.  Co-trimoxazole versus non-absorbable antibiotics in acute leukaemia.

Authors:  J G Watson; B Jameson; R L Powles; T J McElwain; D N Lawson; I Judson; G R Morgenstern; H Lumley; H E Kay
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

4.  A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients.

Authors:  J W Yates; J F Holland
Journal:  Cancer       Date:  1973-12       Impact factor: 6.860

5.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

6.  Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukaemia.

Authors:  I D Starke; P Donnelly; D Catovsky; J Darrell; S A Johnson; J M Goldman; D A Galton
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

7.  Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia.

Authors:  A W Dekker; M Rozenberg-Arska; J J Sixma; J Verhoef
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

8.  Infection prophylaxis in acute leukaemia patients: comparison of selective and total antimicrobial decontamination of the gastrointestinal tract.

Authors:  S Bhaduri; E Kurrle; D Krieger; H Pflieger; R Arnold; B Kubanek; H Heimpel
Journal:  Folia Haematol Int Mag Klin Morphol Blutforsch       Date:  1982

9.  Causes of death in adults with acute leukemia.

Authors:  H Y Chang; V Rodriguez; G Narboni; G P Bodey; M A Luna; E J Freireich
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

10.  High remission-induction rate in acute myeloid leukaemia.

Authors:  R P Gale; M J Cline
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

View more
  11 in total

Review 1.  Selective decontamination in neutropenic patients.

Authors:  E Kurrle; T Schmeiser; W Kern
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

2.  Therapy for acute myeloid leukemia in 119 adults: a comparison of two treatment protocols.

Authors:  H Link; H M Frauer; P Ostendorf; H D Waller
Journal:  Blut       Date:  1985-07

Review 3.  Hematological side effects of co-trimoxazole.

Authors:  H Heimpel; A Raghavachar
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 4.  Selective antimicrobial modulation of the intestinal flora. Prophylaxis against infection in neutropenic patients.

Authors:  H F Guiot; R van Furth
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

5.  Antimicrobial prophylaxis in immunocompromised patients.

Authors:  J H Hartlapp
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 6.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

7.  Binding to and antibacterial effect of aztreonam, temocillin, gentamicin and tobramycin on human faeces.

Authors:  M P Hazenberg; A M Pennock-Schröder; J P van de Merwe
Journal:  J Hyg (Lond)       Date:  1985-10

8.  [Bone marrow transplantation in panmyelopathy, acute leukemia and chronic myelocytic leukemia: results of the Ulm Transplantation Group].

Authors:  R Arnold; T Schmeiser; W Friedrich; F Carbonell; S F Goldmann; W Heit; E Kohne; E Kurrle; E Röttinger; M Wannenmacher
Journal:  Klin Wochenschr       Date:  1984-06-15

9.  Prevention of infection in acute leukemia: a prospective randomized study on the efficacy of two different drug regimens for antimicrobial prophylaxis.

Authors:  E Kurrle; A W Dekker; W Gaus; E Haralambie; D Krieger; M Rozenberg-Arska; H G de Vries-Hospers; D van der Waaij; F Wendt
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

10.  Ofloxacin for prevention of bacterial infections in granulocytopenic patients.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.